Oncofetal antigen binding proteins and related compositions and methods

US10239949B2 · kind B2 · utility

Assignees

• Aptevo Research and Development LLC · US
• ALLIGATOR BIOSCIENCE AB · SE

Inventors

• David Bienvenue · Seattle, US
• Gabriela Hernandez-Hoyos · Seattle, US
• Lynda Misher · Seattle, US
• Danielle M. Mitchell · Seattle, US
• Peter Ellmark · Lund, SE
• Anna Sall · Lund, SE
• Christina Furebring · Lund, SE
• Laura Von Schantz · Lund, SE
• Sara Fritzell · Lund, SE
• Laura Varas · Lund, SE

Key dates

• Filing date: Jul 20, 2018
• Grant date: Mar 26, 2019
• Expiry date: Jul 20, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2800/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present disclosure relates to protein molecules that specifically bind to 5T4 and/or 4-1BB. The molecules may have at least one humanized 5T4-binding or 4-1BB-binding domain. Such molecules are useful for the treatment of cancer. The protein molecule binding to 5T4 or 4-1BB may have a second binding domain that binds to another target. The molecules may bind both 5T4-expressing cells and a cell-surface molecule expressed by an effector cell to enhance effector cell activation, proliferation, survival and/or effector-cell mediated cytotoxicity. The disclosure also provides pharmaceutical compositions comprising the 5T4-binding or 4-1BB-binding polypeptide or protein molecules, nucleic acid molecules encoding these polypeptides and methods of making and using these molecules.